Ascletis Pharma Inc. (2VJ.F)

0.1450 +0.0150 (+11.54%) As of 09:59AM CEST. Market open.

Ascletis Pharma Inc.

Building D
12th Floor 198 Qidi Road, HIPARK Xiaoshan District
Hangzhou
China
86 571 8538 9730
https://www.ascletis.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 219

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jinzi Jason Wu Ph.D.	Founder, Chairman & CEO	2.93M	N/A	1964
Ms. Hejingdao Wu	Senior VP of Operations & Executive Director	345.57k	N/A	1975
Ms. Yuemei Yan	Senior Vice President of Clinical Development Operations	N/A	N/A	1970
Dr. Kristjan Sigurdur Gudmundsson	Senior Consultant & Head of Discovery	N/A	N/A	1968
Dr. George Zhengzhi Hill	Senior Consultant & Chief Medical Advisor	N/A	N/A	1951
Mr. John P. Gargiulo M.B.A.	Chief Business Officer	N/A	N/A	N/A
Mr. Ming Fai Chung CPA	Company Secretary	N/A	N/A	1980

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Corporate Governance

Ascletis Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.